ArticleToxics2025

Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality Analysis Based on FDA Adverse Event Reporting System Database.

Yun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.